Cargando…

Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management

Hyperinsulinism (HI) is the leading cause of persistent hypoglycemia in children, which if unrecognized may lead to development delays and permanent neurologic damage. Prompt recognition and appropriate treatment of HI are essential to avoid these sequelae. Major advances have been made over the pas...

Descripción completa

Detalles Bibliográficos
Autores principales: Lord, Katherine, De León, Diva D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573904/
https://www.ncbi.nlm.nih.gov/pubmed/23384201
http://dx.doi.org/10.1186/1687-9856-2013-3
_version_ 1782259521625784320
author Lord, Katherine
De León, Diva D
author_facet Lord, Katherine
De León, Diva D
author_sort Lord, Katherine
collection PubMed
description Hyperinsulinism (HI) is the leading cause of persistent hypoglycemia in children, which if unrecognized may lead to development delays and permanent neurologic damage. Prompt recognition and appropriate treatment of HI are essential to avoid these sequelae. Major advances have been made over the past two decades in understanding the molecular basis of hyperinsulinism and mutations in nine genes are currently known to cause HI. Inactivating K(ATP) channel mutations cause the most common and severe type of HI, which occurs in both a focal and a diffuse form. Activating mutations of glutamate dehydrogenase (GDH) lead to hyperinsulinism/hyperammonemia syndrome, while activating mutations of glucokinase (GK), the “glucose sensor” of the beta cell, causes hyperinsulinism with a variable clinical phenotype. More recently identified genetic causes include mutations in the genes encoding short-chain 3-hydroxyacyl-CoA (SCHAD), uncoupling protein 2 (UCP2), hepatocyte nuclear factor 4-alpha (HNF-4α), hepatocyte nuclear factor 1-alpha (HNF-1α), and monocarboyxlate transporter 1 (MCT-1), which results in a very rare form of HI triggered by exercise. For a timely diagnosis, a critical sample and a glucagon stimulation test should be done when plasma glucose is < 50 mg/dL. A failure to respond to a trial of diazoxide, a K(ATP) channel agonist, suggests a K(ATP) defect, which frequently requires pancreatectomy. Surgery is palliative for children with diffuse K(ATP)HI, but children with focal K(ATP)HI are cured with a limited pancreatectomy. Therefore, distinguishing between diffuse and focal disease and localizing the focal lesion in the pancreas are crucial aspects of HI management. Since 2003, (18) F-DOPA PET scans have been used to differentiate diffuse and focal disease and localize focal lesions with higher sensitivity and specificity than more invasive interventional radiology techniques. Hyperinsulinism remains a challenging disorder, but recent advances in the understanding of its genetic basis and breakthroughs in management should lead to improved outcomes for these children.
format Online
Article
Text
id pubmed-3573904
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35739042013-02-16 Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management Lord, Katherine De León, Diva D Int J Pediatr Endocrinol Review Hyperinsulinism (HI) is the leading cause of persistent hypoglycemia in children, which if unrecognized may lead to development delays and permanent neurologic damage. Prompt recognition and appropriate treatment of HI are essential to avoid these sequelae. Major advances have been made over the past two decades in understanding the molecular basis of hyperinsulinism and mutations in nine genes are currently known to cause HI. Inactivating K(ATP) channel mutations cause the most common and severe type of HI, which occurs in both a focal and a diffuse form. Activating mutations of glutamate dehydrogenase (GDH) lead to hyperinsulinism/hyperammonemia syndrome, while activating mutations of glucokinase (GK), the “glucose sensor” of the beta cell, causes hyperinsulinism with a variable clinical phenotype. More recently identified genetic causes include mutations in the genes encoding short-chain 3-hydroxyacyl-CoA (SCHAD), uncoupling protein 2 (UCP2), hepatocyte nuclear factor 4-alpha (HNF-4α), hepatocyte nuclear factor 1-alpha (HNF-1α), and monocarboyxlate transporter 1 (MCT-1), which results in a very rare form of HI triggered by exercise. For a timely diagnosis, a critical sample and a glucagon stimulation test should be done when plasma glucose is < 50 mg/dL. A failure to respond to a trial of diazoxide, a K(ATP) channel agonist, suggests a K(ATP) defect, which frequently requires pancreatectomy. Surgery is palliative for children with diffuse K(ATP)HI, but children with focal K(ATP)HI are cured with a limited pancreatectomy. Therefore, distinguishing between diffuse and focal disease and localizing the focal lesion in the pancreas are crucial aspects of HI management. Since 2003, (18) F-DOPA PET scans have been used to differentiate diffuse and focal disease and localize focal lesions with higher sensitivity and specificity than more invasive interventional radiology techniques. Hyperinsulinism remains a challenging disorder, but recent advances in the understanding of its genetic basis and breakthroughs in management should lead to improved outcomes for these children. BioMed Central 2013 2013-02-06 /pmc/articles/PMC3573904/ /pubmed/23384201 http://dx.doi.org/10.1186/1687-9856-2013-3 Text en Copyright ©2013 Lord and De León; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Lord, Katherine
De León, Diva D
Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management
title Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management
title_full Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management
title_fullStr Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management
title_full_unstemmed Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management
title_short Monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management
title_sort monogenic hyperinsulinemic hypoglycemia: current insights into the pathogenesis and management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573904/
https://www.ncbi.nlm.nih.gov/pubmed/23384201
http://dx.doi.org/10.1186/1687-9856-2013-3
work_keys_str_mv AT lordkatherine monogenichyperinsulinemichypoglycemiacurrentinsightsintothepathogenesisandmanagement
AT deleondivad monogenichyperinsulinemichypoglycemiacurrentinsightsintothepathogenesisandmanagement